Richard Rupp, MD &ndash; Projects/Grants

Completed

An Expanded Access Treatment Protocol for Zmapp TM for Patients with Ebola Virus Disease (EVD) or Ebola Virus Exposure

Rupp, R.

ICON Government & Public Health Solution

5/1/18 → 6/26/19

Project: Other project

A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 (PE34) Process Administered Concomitantly with M-M-R II

Rupp, R.

Merck Sharp & Dohme Corporation

8/21/17 → 8/20/19

Project: Other project

lmmunogenicity, reactogenicityan safetystudyof Pediarix, Hiberix, and Prevnar 13 co-administered with two diff'erent formulations of GSK Biologicals' HRVvaccine ( 444563) in healthy infants 6-12 weeks of age

Rupp, R.

GlaxoSmithKline Pharmaceuticals

8/18/17 → 8/17/19

Project: Other project

Vaccine and Treatment Evaluation Units (VTEU) Overall Administration, Clinical Operations Support and Concept and Protocol Development and Implementation for Task Areas B & C Task Order FY.2017.B8C12.0080

Rupp, R.

BAYLOR COLLEGE OF MEDICINE

7/28/17 → 7/27/19

Project: Other project

GV29893 A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY, ADMINISTERED AS MONOTHERAPY FOR THE TREATMENT OF ACUTE UNCOMPLICATED SEASONAL INFLUENZA A INFECTION IN OTHERWISE HEALTHY ADULTS

Rupp, R.

Genentech, Inc.

10/27/16 → 10/26/18

Project: Other project

Vaccine and Treatment Evaluation Units (VTEU) Protocol Development, Implementation and Assays Task Area B-D Task Order 15-0066.B1C1D1.0041

Rupp, R.

BAYLOR COLLEGE OF MEDICINE

9/16/16 → 6/30/19

Project: Other project

V114-005 A Phase l-ll, randomized, Double-Blind, Study to Evaluate the safety, Tolerability, and Immunogenicity of Different formulations of V114 in Healthy Adults and Infants

Rupp, R.

Merck Sharp & Dohme Corporation

8/18/15 → 8/17/18

Project: Other project

A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of Three Consistency Lots and a high Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults

Rupp, R.

Merck Sharp & Dohme Corporation

8/4/15 → 9/30/18

Project: Other project

V160-001-002: A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults

Rupp, R.

Merck Sharp & Dohme Corporation

6/27/14 → 6/26/18

Project: Other project

A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of VARIVAX New Seed Process (NSP) Administered Concomitantly with M-M-R II

Rupp, R.

Merck Sharp & Dohme Corporation

4/30/14 → 5/1/16

Project: Other project

V503-010-0007: A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, administered in Preadolescents and Adolescents (9 to 14 yea

Rupp, R.

Merck Sharp & Dohme Corporation

2/7/14 → 2/6/19

Project: Other project

V114-004 A Phase I-II, Randomized, Double-Blind, study to Evaluate the Safty, Tolerability, and Immunogenicity of V114 in Healthy Adults and Infants

Rupp, R.

Merck Sharp & Dohme Corporation

12/10/13 → 12/31/17

Project: Other project

Protocol No.: V503-003-00-0255: "A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillornavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year Old Men and 16- to 26-Year Old Women"

Rupp, R.

Merck Sharp & Dohme Corporation

1/3/13 → 1/2/15

Project: Other project

Phase 1b, Partial-Blind, Parallel Group, Randomized Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine (DENVax) Administered Intradermally Using Needle or a Needle-Free PharmaJet Injector in Healthy Adults

Rupp, R.

Takeda Vaccines Inc

12/31/12 → 12/14/16

Project: Other project

Protocol No.: V221-027; A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made with Alternative Manufacturing Process (AMP)

Rupp, R.

Merck Sharp & Dohme Corporation

6/21/12 → 6/20/14

Project: Other project

Protocol No.: V59P23; "A Phase 3b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine when Administered with Routine Infant Vaccinations to Healthy Infants"

Rupp, R.

Novartis Vaccines & Diagnostics Inc

4/27/12 → 4/26/14

Project: Other project

Protocol: V114-002-008, "A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX 23) and Prevnar 13 (Pneumococcal 13-Valent

Rupp, R.

Merck Sharp & Dohme Corporation

3/1/12 → 6/14/19

Project: Other project

Protocol Number: INV-DEN-104; A Randomized, Phase 1b Study to Investigate the Safety and Immunogenicty of Various Schedules of Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers Between the Ages of 18-45 Years

Rupp, R.

Takeda Vaccines Inc

12/20/11 → 9/1/15

Project: Other project

Protocol B1971011: A Phase 2, Randomized, Single-Blind Trial, To Asess the Safety, Tolerability and Immunogenicity of Gardasil Vaccine and rLP2086 Vaccine When Administered Concomitantly in Healthy Subjects Aged >/= 11 to </=17 Years

Rupp, R.

Pfizer, Inc.

8/1/11 → 1/1/15

Project: Other project

08-0013 Eval Control Measures

Rupp, R.

BAYLOR COLLEGE OF MEDICINE

7/1/09 → 8/31/17

Project: Other project

Protocol No. V59P13E1: A Phase 3, Open-Label,Multi-Center Study to Evaluate the Persistence of Novartis MenACWY Antibody Response in Adolescents who Have Previously received either Novartis MenACWY Conjugate Vaccine or Menactra

Rupp, R.

Novartis Vaccines & Diagnostics Inc

2/2/09 → 2/1/15

Project: Other project

Novartis V59P13: A Phase III, Randomized, Ovserver-blind, Controlled, Multi-Center Study to Evaluate the Lot to Lot Consistency of Novartis Meningococcal ACWY Conjugate Vaccine when One Dose is Administered to Healthy Adolescents 11-18 Years of Age and t

Rupp, R.

Novartis Pharmaceuticals Corporation

2/10/07 → 3/31/15

Project: Other project